MAST Research Program

The MAST Program is proud to announce a Phase 2 clinical study to evaluate the next-generation compound designed to target the small intestinal microbiome. Building on the science of rifaximin, this new compound is being studied at Cedars-Sinai as a potential treatment for irritable bowel syndrome with diarrhea (IBS-D). This multi-center Phase 2 trial is enrolling its first patient this week and reflects the direct translation of MAST-led research into clinical investigation. Our work has helped identify hydrogen sulfide as a key driver of gastrointestinal symptoms, laying the scientific foundation for targeted therapeutic advances. At MAST, this is what progress looks like: translating cutting-edge microbiome science into meaningful advances for patients with complex gastrointestinal disorders. Because better science leads to better care for you. #ClinicalTrials #MASTProgram #CedarsSinai #Microbiome #IBS #SIBO #IMO #PCOS #Obesity #GutMicrobiome